Clinical trial results:
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderate to Severe Psoriasis

Summary

EudraCT number	2022-002887-59
Trial protocol	PL
Global end of trial date	20 December 2023

Results information

Result version number	v1 (current)
This version publication date	27 September 2026
First version publication date	27 September 2026

Trial information

Trial identification

Sponsor protocol code	VTX958-201

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05655299
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Ventyx Biosciences, Inc.
Sponsor organisation address	662 Encinitas Boulevard, Suite 250, Encinitas, United States, CA 92024
Public contact	Ventyx Clinical Trial Contact, Ventyx Biosciences, Inc., +1 888-411-5176108, ClinicalTrials@ventyxbio.com
Scientific contact	Ventyx Clinical Trial Contact, Ventyx Biosciences, Inc., +1 888-411-5176108, ClinicalTrials@ventyxbio.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	20 December 2023
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	20 December 2023
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To determine the efficacy of VTX958 after treatment for 16 weeks in participants with moderate to severe psoriasis.
To evaluate the safety and tolerability of VTX958 during the placebo controlled treatment period in participants with moderate to severe psoriasis.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	17 November 2022
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 74
Country: Number of subjects enrolled	Canada: 42
Country: Number of subjects enrolled	United States: 106
Worldwide total number of subjects	222
EEA total number of subjects	74

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	201

From 65 to 84 years	21
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

A total of 222 participants were enrolled and randomized with 220 participants receiving at least 1 dose of study treatment; 2 randomized participants withdrew consent prior to receiving their first dose of study treatment.

Pre-assignment

Screening details:

Participants were randomized to VTX958 (300 mg BID, 225 mg BID, 300 mg QD, or 50 mg BID) or placebo. Participants achieving PASI-75 by the end of period 1 continued their assigned VTX958 dose during the LTE period, whereas participants not achieving PASI-75 by the end of period 1 and participants assigned to placebo received VTX958 300 mg BID.

Period 1

Period 1 title	Period 1: Placebo Controlled (PC)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	VTX958 300 mg BID (PC)

Arm description:

Participants received VTX958 300 milligram (mg) administered orally twice daily (BID) to maintain the blind in Period 1.

Arm type	Experimental
Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 300 mg BID, administered as 2 tablets of VTX958 125 mg and 1 tablet of VTX958 50 mg.

Arm title	VTX958 225 mg BID (PC)

Arm description:

Participants received VTX958 225 mg administered orally BID to maintain the blind in Period 1.

Arm type	Experimental
Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 225 mg BID, administered as 1 tablet of VTX958 125 mg and 2 tablets of VTX958 50 mg.

Arm title	VTX958 300 mg QD (PC)

Arm description:

Participants received VTX958 300 mg administered orally once daily (QD), and matching placebo tablets administered orally QD to maintain the blind in Period 1

Arm type	Experimental

Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 300 mg QD, administered as 2 tablets of VTX958 125 mg and 1 tablet of VTX958 50 mg.

Investigational medicinal product name	Placebo
Investigational medicinal product code	Placebo
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received 3 matching placebo tablets QD.

Arm title	VTX958 50 mg BID (PC)

Arm description:

Participants received VTX958 50 mg and matching placebo tablets administered orally BID to maintain the blind in Period 1.

Arm type	Experimental
Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 50 mg BID, administered as 1 tablet of VTX958 50 mg.

Investigational medicinal product name	Placebo
Investigational medicinal product code	Placebo
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received 2 placebo tablets BID.

Arm title	Placebo BID (PC)

Arm description:

Participants received placebo tablets matched to VTX958 administered BID to maintain the blind in Period 1.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	Placebo
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received 3 matching placebo tablets QD.

Number of subjects in period 1	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)
Started	44	45	44
Safety Population	43	45	44
Completed	34	35	38
Not completed	10	10	6
Adverse event, non-fatal	5	5	2
Lost to follow-up	1	3	2
Withdrawal by subject	4	2	2
Lack of efficacy	-	-	-

Number of subjects in period 1	VTX958 50 mg BID (PC)	Placebo BID (PC)
Started	45	44
Safety Population	45	43
Completed	40	36
Not completed	5	8
Adverse event, non-fatal	1	1
Lost to follow-up	1	3
Withdrawal by subject	3	3
Lack of efficacy	-	1

Period 2	
Period 2 title	Period 2: Long Term Extension (LTE)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Long Term Extension Period (LTE): VTX958 300 mg BID

Arm description:

Participants who received VTX958 300 mg dose administered orally BID in Period 2.

Arm type	Experimental
Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 300mg BID, administered as 2 tablets of VTX958 125 mg and 1 tablet of VTX958 50 mg..

Arm title	LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID

Arm description:

Participants who received VTX958 225 mg at Period 1 continued to receive VTX958 225 mg dose administered orally BID in Period 2.

Arm type	Experimental
Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 225 mg BID, administered as 1 tablet of VTX958 125 mg and 2 tablets of VTX958 50 mg.

Arm title	LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD

Arm description:

Participants who received VTX958300 mg at Period 1 continued to receive VTX958 300 mg dose administered orally QD in Period 2.

Arm type	Experimental
Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 300 mg QD, administered as 2 tablets of VTX958 125 mg and 1 tablet of VTX958 50 mg.

Investigational medicinal product name	Placebo
Investigational medicinal product code	Placebo
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received 3 tablets of placebo QD.

Arm title	LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID

Arm description:

Participants who received VTX958 50 mg at Period 1 continued to receive VTX958 50 mg dose administered orally BID in Period 2.

Arm type	Experimental
Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 50 mg BID, administered as 1 tablet of VTX958 50 mg.

Investigational medicinal product name	Placebo
Investigational medicinal product code	Placebo
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received 2 tablets of placebo BID

Number of subjects in period 2[1]	Long Term Extension Period (LTE): VTX958 300 mg BID	LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID	LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD
Started	134	20	14
Completed	23	1	3
Not completed	111	19	11
Physician decision	2	-	-
Adverse event, non-fatal	1	-	-
Pregnancy	1	-	-
Study terminated by sponsor	95	19	10
Lost to follow-up	3	-	-
Withdrawal by subject	7	-	-
Lack of efficacy	2	-	1

Number of subjects in period 2[1]	LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID
Started	11
Completed	1
Not completed	10
Physician decision	-
Adverse event, non-fatal	-
Pregnancy	-
Study terminated by sponsor	8
Lost to follow-up	-
Withdrawal by subject	1
Lack of efficacy	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: 4 participants declined to continue into the LTE period, which is why fewer participants entered the LTE period than completed the Placebo-controlled period.

Period 3

Period 3 title	Period 3: Open Label Extension (OLE)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Arm title	Open Label Extension (OLE): VTX958 300 mg BID

Arm description:

Participants received VTX958 300 mg dose administered orally BID in Period 3.

Arm type	Experimental
Investigational medicinal product name	VTX958
Investigational medicinal product code	VTX958
Other name	
Pharmaceutical forms	Film-coated tablet
Routes of administration	Oral use

Dosage and administration details:

Participants received VTX958 300 mg BID, administered as 2 tablets of VTX958 125 mg and 1 tablet of VTX958 50 mg.

Number of subjects in period 3[2]	Open Label Extension (OLE): VTX958 300 mg BID
Started	27
Completed	0
Not completed	27
Study terminated by sponsor	26
Withdrawal by subject	1

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.
Justification: 1 participant declined to continue into the OLE period, which is why fewer participants entered the OLE period than completed the LTE period.

Baseline characteristics

Reporting groups	
Reporting group title	VTX958 300 mg BID (PC)
Reporting group description:	
Participants received VTX958 300 milligram (mg) administered orally twice daily (BID) to maintain the blind in Period 1.	
Reporting group title	VTX958 225 mg BID (PC)
Reporting group description:	
Participants received VTX958 225 mg administered orally BID to maintain the blind in Period 1.	
Reporting group title	VTX958 300 mg QD (PC)
Reporting group description:	
Participants received VTX958 300 mg administered orally once daily (QD), and matching placebo tablets administered orally QD to maintain the blind in Period 1	
Reporting group title	VTX958 50 mg BID (PC)
Reporting group description:	
Participants received VTX958 50 mg and matching placebo tablets administered orally BID to maintain the blind in Period 1.	
Reporting group title	Placebo BID (PC)
Reporting group description:	
Participants received placebo tablets matched to VTX958 administered BID to maintain the blind in Period 1.	

Reporting group values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)
Number of subjects	44	45	44
Age categorical			
2 randomized participants withdrew consent prior to receiving their first dose of study treatment.			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	39	40	39
From 65-84 years	5	5	5
85 years and over	0	0	0
Gender categorical Units: Subjects			
Female	15	13	14
Male	29	32	30
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	6	12	10
Not Hispanic or Latino	38	33	34
Unknown or Not Reported	0	0	0
Race (NIH/OMB) Units: Subjects			

American Indian or Alaska Native	0	0	0
Asian	2	1	3
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	2	3	2
White	40	41	38
More than one race	0	0	1
Unknown or Not Reported	0	0	0
Region of Enrollment Units: Subjects			
Canada	6	11	8
Poland	23	11	11
United States	15	23	25

Reporting group values	VTX958 50 mg BID (PC)	Placebo BID (PC)	Total
Number of subjects	45	44	222
Age categorical			
2 randomized participants withdrew consent prior to receiving their first dose of study treatment.			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	42	41	201
From 65-84 years	3	3	21
85 years and over	0	0	0
Gender categorical Units: Subjects			
Female	17	15	74
Male	28	29	148
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	7	4	39
Not Hispanic or Latino	38	40	183
Unknown or Not Reported	0	0	0
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	4	2	12
Native Hawaiian or Other Pacific Islander	0	1	1
Black or African American	1	6	14
White	40	33	192
More than one race	0	2	3
Unknown or Not Reported	0	0	0
Region of Enrollment Units: Subjects			
Canada	10	7	42

Poland	12	17	74
United States	23	20	106

End points reporting groups

Reporting group title	VTX958 300 mg BID (PC)
Reporting group description:	
Participants received VTX958 300 milligram (mg) administered orally twice daily (BID) to maintain the blind in Period 1.	
Reporting group title	VTX958 225 mg BID (PC)
Reporting group description:	
Participants received VTX958 225 mg administered orally BID to maintain the blind in Period 1.	
Reporting group title	VTX958 300 mg QD (PC)
Reporting group description:	
Participants received VTX958 300 mg administered orally once daily (QD), and matching placebo tablets administered orally QD to maintain the blind in Period 1	
Reporting group title	VTX958 50 mg BID (PC)
Reporting group description:	
Participants received VTX958 50 mg and matching placebo tablets administered orally BID to maintain the blind in Period 1.	
Reporting group title	Placebo BID (PC)
Reporting group description:	
Participants received placebo tablets matched to VTX958 administered BID to maintain the blind in Period 1.	
Reporting group title	Long Term Extension Period (LTE): VTX958 300 mg BID
Reporting group description:	
Participants who received VTX958 300 mg dose administered orally BID in Period 2.	
Reporting group title	LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID
Reporting group description:	
Participants who received VTX958 225 mg at Period 1 continued to receive VTX958 225 mg dose administered orally BID in Period 2.	
Reporting group title	LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD
Reporting group description:	
Participants who received VTX958300 mg at Period 1 continued to receive VTX958 300 mg dose administered orally QD in Period 2.	
Reporting group title	LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID
Reporting group description:	
Participants who received VTX958 50 mg at Period 1 continued to receive VTX958 50 mg dose administered orally BID in Period 2.	
Reporting group title	Open Label Extension (OLE): VTX958 300 mg BID
Reporting group description:	
Participants received VTX958 300 mg dose administered orally BID in Period 3.	

Primary: Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI75) at Week 16

End point title	Period 1: Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI75) at Week 16

End point description:

Participants achieving a ≥75% reduction from baseline in Psoriasis Area and Severity Index (PASI) score (PASI 75) at Week 16 were considered responders. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region

and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.
All randomised participants who received at least 1 dose of the study intervention.

End point type	Primary

End point timeframe:

Week 16

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	45	44	45
Units: Percentage of participants				
number (not applicable)	48.8	48.9	31.8	24.4

End point values	Placebo BID (PC)			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Percentage of participants				
number (not applicable)	14.0			

Statistical analyses

Statistical analysis title	VTX958 300 mg BID (PC), Placebo BID (PC)
Comparison groups	VTX958 300 mg BID (PC) v Placebo BID (PC)
Number of subjects included in analysis	86
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	5.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.013
upper limit	16.531

Statistical analysis title	VTX958 225 mg BID (PC), Placebo BID (PC)
Comparison groups	VTX958 225 mg BID (PC) v Placebo BID (PC)

Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	6.05
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.086
upper limit	17.542

Statistical analysis title	VTX958 300 mg QD (PC), Placebo BID (PC)
Comparison groups	VTX958 300 mg QD (PC) v Placebo BID (PC)
Number of subjects included in analysis	87
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.045
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	3
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.002
upper limit	8.98

Statistical analysis title	VTX958 50 mg BID (PC), Placebo BID (PC)
Comparison groups	VTX958 50 mg BID (PC) v Placebo BID (PC)
Number of subjects included in analysis	88
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	2.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.673
upper limit	6.517

Primary: Period 1: Number of Participants With Treatment emergent adverse events

(TEAEs) and Serious adverse events (SAEs) Observed During the Study of VTX958

End point title	Period 1: Number of Participants With Treatment emergent adverse events (TEAEs) and Serious adverse events (SAEs) Observed During the Study of VTX958[1]

End point description:

The number of participants with TEAEs and SAEs observed during the study of VTX958.
A TEAE is any condition that was not present prior to treatment with the study product but appeared following treatment, was present at treatment initiation but worsened during treatment, or was present at treatment initiation but resolved and then reappeared while the individual was on treatment (regardless of the intensity of the AE when the treatment was initiated).
An SAE or reaction is any untoward medical occurrence that, at any dose has any of the following consequences:
- Results in death
- Is life-threatening
- Requires in-patient hospitalization or prolongation of existing hospitalization
- Results in persistent or significant disability/incapacity
- Is a congenital anomaly/birth defect

All randomised participants who received at least 1 dose of the study intervention.

End point type	Primary

End point timeframe:

Baseline up to week 16

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This endpoint was analyzed descriptively only. Results are presented as counts and percentages of participants with TEAEs and SAEs. No statistical inferences were prespecified in the SAP. Therefore, no formal statistical analysis was performed.

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	45	44	45
Units: participants				
TEAE's	25	28	20	17
SAE's	1	0	1	1

End point values	Placebo BID (PC)			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: participants				
TEAE's	18			
SAE's	1			

Statistical analyses

No statistical analyses for this end point

Secondary: Period 1: Percentage of Participants Achieving a static Physician's Global Assessment(sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16

End point title	Period 1: Percentage of Participants Achieving a static Physician's Global Assessment(sPGA) Score of 0 (Clear) or 1 (Almost Clear) With ≥2 Grade Improvement From Baseline at Week 16

End point description:

Percentage of participants achieving a sPGA score of 0 (clear) or 1 (almost clear) with ≥2grade improvement from baseline at Week 16. The investigator assessed psoriasis severity on a 5-point scale from 0 (clear) to 4 (severe):
0 = Clear: No signs of psoriasis; post-inflammatory hyperpigmentation may occur
= Almost clear: Normal to pink lesions; no thickening; no or minimal focal scaling
= Mild: Pink to light red color; slight thickening; mainly fine scaling
= Moderate: Dull bright red erythema; moderate thickening; moderate scaling
= Severe: Bright to deep red; severe thickening with hard edges; coarse scaling covering most or all lesions

All randomised participants who received at least one dose of the study intervention.

End point type	Secondary

End point timeframe:

Week 16

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	45	44	45
Units: Percentage of participants				
number (not applicable)	37.2	40.0	20.5	13.3

End point values	Placebo BID (PC)			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Percentage of participants				
number (not applicable)	7.0			

Statistical analyses

No statistical analyses for this end point

Secondary: Period 1: Change From Baseline in PASI Score at Week 16

End point title	Period 1: Change From Baseline in PASI Score at Week 16

End point description:

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects.
The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0

to 72, with higher values indicating greater severity.

All randomised participants who received at least 1 dose of the study intervention and had evaluable efficacy data for this outcome at the specified timepoint.

End point type	Secondary

End point timeframe:

Baseline, Week 16

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	37	39	40
Units: score on a scale				
least squares mean (standard error)	-13.58 (± 1.160)	-13.20 (± 1.144)	-9.79 (± 1.123)	-7.88 (± 1.115)

End point values	Placebo BID (PC)			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: score on a scale				
least squares mean (standard error)	-5.81 (± 1.162)			

Statistical analyses

No statistical analyses for this end point

Secondary: Period 1: Percent Change From Baseline in PASI Score at Week 16

End point title	Period 1: Percent Change From Baseline in PASI Score at Week 16

End point description:

Least square mean was determined with mixed model repeated measures (MMRM) using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, baseline PASI score, prior biologic therapy (Yes/No), and geographic region as fixed effects.
The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

All randomised participants who received at least 1 dose of the study intervention and had evaluable efficacy data for this outcome at the specified timepoint.

End point type	Secondary

End point timeframe:

Baseline, Week 16

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	37	39	40
Units: Percent change				
least squares mean (standard error)	-74.94 (± 5.365)	-72.18 (± 5.290)	-54.82 (± 5.186)	-45.22 (± 5.155)

End point values	Placebo BID (PC)			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Percent change				
least squares mean (standard error)	-33.44 (± 5.356)			

Statistical analyses

No statistical analyses for this end point

Secondary: Period 1: Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI 90 at Week 16

End point title	Period 1: Percentage of Participants Achieving ≥90% Reduction From Baseline in PASI 90 at Week 16

End point description:

Percentage of participants achieving ≥90% reduction from baseline in PASI90 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

All randomised participants who received at least 1 dose of the study intervention.

End point type	Secondary

End point timeframe:

Week 16

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	45	44	45
Units: Percentage of participants				
number (not applicable)	41.9	37.8	15.9	11.1

End point values	Placebo BID (PC)			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Percentage of participants				
number (not applicable)	4.7			

Statistical analyses

No statistical analyses for this end point

Secondary: Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI 100 at Week 16

End point title	Period 1: Percentage of Participants Achieving ≥100% Reduction From Baseline in PASI 100 at Week 16

End point description:

Percentage of participants achieving ≥100% reduction from baseline in PASI100 at Week 16. The PASI measures psoriasis severity based on lesion characteristics and body surface area (BSA) affected. Erythema, thickness, and scaling are each scored from 0 (none) to 4 (very severe) across four regions: head, trunk, upper limbs, and lower limbs. Area involvement in each region is graded from 0 (none) to 6 (90-100%). The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region and a region-specific BSA weight (0.1, 0.3, 0.2, 0.4). Regional scores are summed to give a total PASI score ranging from 0 to 72, with higher values indicating greater severity.

All randomised participants who received at least 1 dose of the study intervention.

End point type	Secondary

End point timeframe:

Week 16

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	43	45	44	45
Units: Percentage of participants				
number (not applicable)	14.0	15.6	2.3	4.4

End point values	Placebo BID			

	(PC)			
Subject group type	Reporting group			
Number of subjects analysed	43			
Units: Percentage of participants				
number (not applicable)	0			

Statistical analyses

No statistical analyses for this end point

Secondary: Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks

End point title	Period 1: Change From Baseline in Dermatology Life Quality Index (DLQI) at 16 Weeks

End point description:

The DLQI is a simple 10-question validated questionnaire where, except for question 7, each question is rated from 0 (Not at all) to 3 (Very much). If question 7 is answered 'yes', this question is assigned a score of 3. If question 7 is answered 'No' or 'Not Relevant', this question is assigned a score 0, except if either 'a lot' or 'a little' is ticked. If so, this question is assigned a score of 2 or 1, respectively. Then, the DLQI total score is the sum of the 10 questions and ranges from 0 to 30, where higher scores indicate worst disease severity.

All randomised participants who received at least 1 dose of the study intervention and had evaluable efficacy sample for this outcome at the specified timepoint.

End point type	Secondary

End point timeframe:

Baseline, Week 16

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	37	39	40
Units: score on a scale				
least squares mean (standard error)	-7.2 (± 0.90)	-8.1 (± 0.88)	-5.4 (± 0.86)	-4.4 (± 0.86)

End point values	Placebo BID (PC)			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: score on a scale				
least squares mean (standard error)	-3.1 (± 0.89)			

Statistical analyses

No statistical analyses for this end point

Secondary: Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16

End point title	Period 1: Change From Baseline in the Percentage of Body Surface Area (BSA) Affected at Week 16

End point description:

Least square mean was determined with MMRM using an unstructured covariance matrix, including treatment, visit, treatment-by-visit interaction, prior biologic treatment for psoriasis (Yes/No), and baseline score as a covariate, with participant as a random effect baseline is the last non-missing pre-dose value.
BSA is a measurement of the affected skin area. It was defined as the percentage of surface area of the body involved with the condition being assessed, (that is, plaque psoriasis). The overall BSA affected by psoriasis plaques is estimated based on the palm area of the participant hand (entire palmar surface or "handprint" including the fingers), which equates to approximately 1% of total BSA. Negative change from baseline indicates improvement.

All randomised participants who received at least 1 dose of the study intervention and had evaluable efficacy data for this given outcome at the specified timepoint.

End point type	Secondary

End point timeframe:

Baseline, Week 16

End point values	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)	VTX958 50 mg BID (PC)
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	37	39	40
Units: Percentage of BSA				
least squares mean (standard error)	-13.48 (± 1.797)	-13.82 (± 1.771)	-9.56 (± 1.739)	-4.94 (± 1.725)

End point values	Placebo BID (PC)			
Subject group type	Reporting group			
Number of subjects analysed	38			
Units: Percentage of BSA				
least squares mean (standard error)	-3.82 (± 1.800)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to 76 weeks

Adverse event reporting additional description:

All randomised participants who received at least 1 dose of the study intervention.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	25.1

Reporting groups

Reporting group title	VTX958 300 mg BID (PC)

Reporting group description:

Participants received one 300 mg VTX958 tablet administered orally twice daily (BID) to maintain the blind in Period 1.

Reporting group title	VTX958 225 mg BID (PC)

Reporting group description:

Participants received one 225 mg VTX958 tablet administered orally BID to maintain the blind in Period 1.

Reporting group title	VTX958 300 mg QD (PC)

Reporting group description:

Participants received 300 mg VTX958 tablet administered orally QD, and matching placebo tablets administered orally QD to maintain the blind in Period 1

Reporting group title	VTX958 50 mg BID (PC)

Reporting group description:

Participants received 50 mg VTX958 tablet administered orally BID to maintain the blind in Period 1.

Reporting group title	Placebo BID (PC)

Reporting group description:

Participants received placebo tablets matched to VTX958 administered BID to maintain the blind in Period 1.

Reporting group title	Long Term Extension Period (LTE): VTX958 300 mg BID

Reporting group description:

Participants who received receive 300 mg VTX958 dose administered orally BID in Period 2.

Reporting group title	LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID

Reporting group description:

Participants who received 225 mg VTX958 at Period 1 continued to receive 225 mg VTX958 dose administered orally BID in Period 2.

Reporting group title	LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD

Reporting group description:

Participants who received 300 mg VTX958 at Period 1 continued to receive 300 mg VTX958 dose administered orally QD in Period 2.

Reporting group title	LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID

Reporting group description:

Participants who received 50 mg VTX958 at Period 1 continued to receive 50 mg VTX958 dose administered orally BID in Period 2.

Reporting group title	Open Label Extension (OLE): VTX958 300 mg BID

Reporting group description:

Participants who received receive 300 mg VTX958 dose administered orally BID in Period 3.

Serious adverse events	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 43 (2.33%)	0 / 45 (0.00%)	1 / 44 (2.27%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	1 / 44 (2.27%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain injury			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			

Chest pain			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Cyclic vomiting syndrome			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 43 (2.33%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	VTX958 50 mg BID (PC)	Placebo BID (PC)	Long Term Extension Period (LTE): VTX958 300 mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 45 (2.22%)	1 / 43 (2.33%)	4 / 132 (3.03%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	0 / 45 (0.00%)	1 / 43 (2.33%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 45 (0.00%)	1 / 43 (2.33%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain injury			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Cyclic vomiting syndrome			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	1 / 132 (0.76%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	1 / 45 (2.22%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			

subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID	LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD	LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 21 (0.00%)	1 / 15 (6.67%)	0 / 11 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Clavicle fracture			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brain injury			
subjects affected / exposed	0 / 21 (0.00%)	1 / 15 (6.67%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			

subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Cyclic vomiting syndrome			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Open Label Extension (OLE): VTX958 300 mg BID		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 27 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			

Clavicle fracture			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Brain injury			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Headache			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Cyclic vomiting syndrome			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			

subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	VTX958 300 mg BID (PC)	VTX958 225 mg BID (PC)	VTX958 300 mg QD (PC)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	15 / 43 (34.88%)	10 / 45 (22.22%)	8 / 44 (18.18%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	6 / 43 (13.95%)	2 / 45 (4.44%)	3 / 44 (6.82%)
occurrences (all)	7	3	4
Aspartate aminotransferase increased			
subjects affected / exposed	4 / 43 (9.30%)	0 / 45 (0.00%)	1 / 44 (2.27%)
occurrences (all)	5	0	2
Blood creatine phosphokinase increased			
subjects affected / exposed	3 / 43 (6.98%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences (all)	3	0	0
Blood creatine increased			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Cataract			

subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	2 / 43 (4.65%)	1 / 45 (2.22%)	0 / 44 (0.00%)
occurrences (all)	2	1	0
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	1 / 43 (2.33%)	3 / 45 (6.67%)	0 / 44 (0.00%)
occurrences (all)	1	3	0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	0 / 44 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	2 / 43 (4.65%)	1 / 45 (2.22%)	1 / 44 (2.27%)
occurrences (all)	2	1	1
Upper respiratory tract infection			
subjects affected / exposed	5 / 43 (11.63%)	3 / 45 (6.67%)	3 / 44 (6.82%)
occurrences (all)	5	3	4
Metabolism and nutrition disorders			
Gout			
subjects affected / exposed	0 / 43 (0.00%)	0 / 45 (0.00%)	1 / 44 (2.27%)
occurrences (all)	0	0	1

Non-serious adverse events	VTX958 50 mg BID (PC)	Placebo BID (PC)	Long Term Extension Period (LTE): VTX958 300 mg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	5 / 45 (11.11%)	5 / 43 (11.63%)	24 / 132 (18.18%)
Investigations			
Alanine aminotransferase increased			

subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	5 / 132 (3.79%)
occurrences (all)	0	0	6
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 45 (0.00%)	1 / 43 (2.33%)	5 / 132 (3.79%)
occurrences (all)	0	1	5
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 45 (0.00%)	2 / 43 (4.65%)	4 / 132 (3.03%)
occurrences (all)	0	2	4
Blood creatine increased			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	3 / 45 (6.67%)	0 / 43 (0.00%)	1 / 132 (0.76%)
occurrences (all)	3	0	1
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	4 / 132 (3.03%)
occurrences (all)	0	0	4
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 45 (2.22%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences (all)	1	0	0

Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 45 (2.22%)	1 / 43 (2.33%)	7 / 132 (5.30%)
occurrences (all)	1	1	7
Upper respiratory tract infection			
subjects affected / exposed	1 / 45 (2.22%)	1 / 43 (2.33%)	5 / 132 (3.79%)
occurrences (all)	1	1	5
Metabolism and nutrition disorders			
Gout			
subjects affected / exposed	0 / 45 (0.00%)	0 / 43 (0.00%)	0 / 132 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	LTE: VTX958 225 mg BID (PC)/ VTX958 225 mg BID	LTE: VTX958 300 mg QD (PC)/ VTX958 300 mg QD	LTE: VTX958 50 mg BID (PC)/ VTX958 50 mg BID
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 21 (14.29%)	4 / 15 (26.67%)	1 / 11 (9.09%)
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 21 (0.00%)	0 / 15 (0.00%)	0 / 11 (0.00%)
occurrences (all)	0	0	0
Blood creatine increased			
subjects affected / exposed	0 / 21 (0.00%)	1 / 15 (6.67%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 21 (0.00%)	1 / 15 (6.67%)	0 / 11 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Cataract			
subjects affected / exposed	0 / 21 (0.00%)	1 / 15 (6.67%)	0 / 11 (0.00%)
occurrences (all)	0	1	0

Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 15 (0.00%) 0	0 / 11 (0.00%) 0
Reproductive system and breast disorders Prostatitis subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 15 (6.67%) 1	0 / 11 (0.00%) 0
Skin and subcutaneous tissue disorders Acne subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 15 (0.00%) 0	0 / 11 (0.00%) 0
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	0 / 15 (0.00%) 0	1 / 11 (9.09%) 1
Infections and infestations Nasopharyngitis subjects affected / exposed occurrences (all) Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 21 (4.76%) 1 2 / 21 (9.52%) 2	0 / 15 (0.00%) 0 1 / 15 (6.67%) 1	0 / 11 (0.00%) 0 0 / 11 (0.00%) 0
Metabolism and nutrition disorders Gout subjects affected / exposed occurrences (all)	0 / 21 (0.00%) 0	1 / 15 (6.67%) 1	0 / 11 (0.00%) 0

Non-serious adverse events	Open Label Extension (OLE): VTX958 300 mg BID		
Total subjects affected by non-serious adverse events subjects affected / exposed	2 / 27 (7.41%)		
Investigations Alanine aminotransferase increased subjects affected / exposed occurrences (all) Aspartate aminotransferase increased	0 / 27 (0.00%) 0		

subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Blood creatine increased			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Eye disorders			
Cataract			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Reproductive system and breast disorders			
Prostatitis			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	1 / 27 (3.70%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	0 / 27 (0.00%)		
occurrences (all)	0		

Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 27 (3.70%) 1		
Metabolism and nutrition disorders Gout subjects affected / exposed occurrences (all)	0 / 27 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported